Abstract: The invention relates to a device for fitting a tablet testing device with a calibration unit. The calibration unit allows of calibrating and adjusting the velocity or breaking force of a breaking jaw of such tablet testing device, for determining the breaking hardness of tablets. The invention allows of calibrating the velocity of movement of the breaking jaw and the breaking hardness applied in timely intervals, as to comply with modern quality control standards for pharmaceutical instruments of measurement. The device is employed for temporarily fitting a tablet testing device for calibration, and is mounted onto the tablet testing device only for the purpose of conducting calibration runs, whilst storing the bulky and huge calibration device separate from the tablet testing device during times of normal operation.

Abstract: A liquid composition comprising a GLP-1 agonist or/and a pharmacologically tolerable salt thereof and, optionally, at least one pharmaceutically acceptable excipient, wherein the composition comprises methionine, as add-on therapy with metformin and/or with long-acting insulin/insulin derivates where appropriate.

Abstract: The invention relates to a long DH (LDH) cassette comprising a recombinant DH construct comprising at least two DH gene segments encoding at least 10 amino acids of the HCDR3 amino acid sequence, wherein at least one of the DH gene segments is a heterologous DH gene segment; an immunoglobulin heavy chain locus and a transgenic non-human animal comprising the same; and their use in producing an immunoglobulin library with long HCDR3 regions.

Abstract: A method for producing a spectacle lens having in particular a diffractive microstructure on at least one lens surface. To this end, a thin structural support layer is initially made available, which on a surface has a microstructure. A lens main body is then cast to the microstructure of the structural support layer.

Abstract: The application relates to an aqueous pharmaceutical formulation comprising 200-1000 U/mL [equimolar to 200-1000 IU human insulin] of insulin glargine.

Abstract: In a method for calibrating a polarization axis measuring device, both flat sides of a calibration element in a polarization axis measuring device are irradiated with polarized light, wherein the method involves aligning in each case at least one polarization direction of the light in a first and/or second rotational position with a principal axis in a predefined angular relationship with respect to a polarization axis of the calibration element. Determining the rotational position of an axis of the calibration element is carried out by determining an angle bisector between the first and second rotational positions of the polarization direction of the incident light. The method involves assigning a predefined angle value for the rotational position of the principal axis of the polarization direction for which the latter is in the predefined angular relationship with respect to the axis of the calibration element inserted as intended.

Abstract: Optimizing and producing a lens by defining an individual eye model, in which a shape of a corneal front surface of a model eye, and a reference aberration at an evaluation surface within the model eye are defined based on individual measurement values for the lens wearer's eye, on standard values, or based on provided individual refraction data; specifying first and second surfaces for the lens to be optimized; determining the path of a main ray through a visual point a surface of the lens into the model eye up to the evaluation surface; evaluating an aberration of a wavefront propagating along the main ray and resulting from a spherical wavefront incident on the first surface of the lens at the evaluation surface in comparison to the reference aberration; and iteratively varying the surface of the lens until the evaluated aberration corresponds to a predetermined target aberration.

Abstract: A liquid composition comprising a GLP-1 agonist and/or a pharmacologically tolerable salt thereof and, optionally, at least one pharmaceutically acceptable excipient, wherein the composition comprises methionine, as add-on therapy with metformin and/or with long-acting insulin/insulin derivatives where appropriate.

Abstract: A liquid composition comprising a GLP-1 agonist or/and a pharmacologically tolerable salt thereof, an insulin or/and a pharmacologically tolerable salt thereof, and, optionally, at least one pharmaceutically acceptable excipient, wherein the composition comprises methionine, as add-on therapy with metformin where appropriate.

Abstract: A liquid composition comprising a GLP-1 agonist or/and a pharmacologically tolerable salt thereof, an insulin or/and a pharmacologically tolerable salt thereof, and, optionally, at least one pharmaceutically acceptable excipient, wherein the composition comprises methionine, as add-on therapy with metformin where appropriate.

Abstract: The invention relates to an electric motor, particularly an “external rotor motor”, comprised of a stator housing and a rotor housing which is rotatable with respect to the stator housing, wherein the rotor housing has a cooling ring disposed on its side which axially faces the stator housing, wherein the stator housing and the cooling ring are each provided with a plurality of first and second cooling fins (the second cooling fins also being referred to as “cooling ribs”) which face each other axially and are disposed so as to be distributed in the respective circumferential directions, which fins/ribs collaborate in flow technology when the rotor housing is in rotating operation; wherein, in an axial plan view, the first cooling fins extend radially outwardly, and the second cooling fins (the cooling ribs) are V-shaped and point in the circumferential direction, wherein a rotary relative movement of the first and second cooling fins (the cooling fins and the cooling ribs) generates a cooling air stream, at

Abstract: In a method for creating a design of a prescription surface of a multifocal lens, in particular for a progressive spectacle lens, at first data and second data for describing at least one aberration of an eye of a proband for a first situation of use and a second situation of use, respectively, are obtained, and then a first set of parameters and a second set of parameters of a predetermined prescription surface equation are determined from the first and second data, wherein the prescription surface equation is assigned to a first reference point of the prescription surface for the first set of parameters, and is assigned to a second reference point of the prescription surface for the second set of parameters.

Abstract: A computer-implemented method for calculating or optimizing a spectacle lens for at least one eye of a spectacle wearer. Refraction data of the at least one eye of the spectacle wearer is collected. An individual eye model is defined, wherein the eye model defines at least the topography of a corneal front surface of the at least one eye, position and power of a lens of the eye, and a retina position of the eye such that the eye exhibits the collected refraction data. A first surface and a second surface for the spectacle lens to be calculated or optimized is specified. The path of a main ray through at least one visual point of at least one spectacle lens surface to be calculated or optimized is determined. A spherical wavefront incident on the first surface of the spectacle lens along the main ray is specified.

Abstract: In a method for calibrating a polarization axis measuring device, both flat sides of a calibration element in a polarization axis measuring device are irradiated with polarized light, wherein the method involves aligning in each case at least one polarization direction of the light in a first and/or second rotational position with a principal axis in a predefined angular relationship with respect to a polarization axis of the calibration element. Determining the rotational position of an axis of the calibration element is carried out by determining an angle bisector between the first and second rotational positions of the polarization direction of the incident light. The method involves assigning a predefined angle value for the rotational position of the principal axis of the polarization direction for which the latter is in the predefined angular relationship with respect to the axis of the calibration element inserted as intended.

Abstract: A device including an image capturing device and a measuring device for determining the distance of at least one eye of a user from the image capturing device. The measuring device comprises a lighting device that is arranged at a specified position relative to the image capturing device and is designed to generate at least one specular light reflection, which has a linear portion, on the cornea of the eye of the user. The measuring device also comprises a distance determining device. The image capturing device is designed to capture at least one image of the specular light reflection in the region of the cornea of the at least one eye of the user.

Abstract: An apparatus for determining optical parameters of a user with spectacles arranged in the use position on the head of the user includes at least one projection device designed and arranged for marking a partial region of the head of the user and/or of the spectacles of the user with a light projection; at least one image recording device designed and arranged for generating image data at least from the marked partial region of the head of the user and/or of the spectacles of the user; and a data processing device with a user data determining device, which is designed to determine user data from the marked partial region of the head and/or of the spectacles on the basis of the generated image data, wherein the user data comprise spatial information in the three-dimensional space of points of the partial region of the head and/or of the spectacles, and a parameter determining device, which is designed to determine optical parameters of the user on the basis of the user data.

Abstract: A liquid composition comprising a GLP-1 agonist and/or a pharocoligically tolerable salt thereof and, optionally, at least one pharmaceutically acceptable excipient, wherein the composition comprises methionine, as add-on therapy with metformin and/or with long-acting insulin/insulin derivatives where appropriate.

Abstract: A liquid composition comprising a GLP-1 agonist or/and a pharmacologically tolerable salt thereof and, optionally, at least one pharmaceutically acceptable excipient, wherein the composition comprises methionine, as add-on therapy with metformin and/or with long-acting insulin/insulin derivates where appropriate.

Abstract: The application relates to an aqueous pharmaceutical formulation comprising 200-1000 U/mL [equimolar to 200-1000 IU human insulin] of insulin glargine.

Abstract: The present invention relates to 1-aza-bicycloalkyl derivatives of Formula (I); wherein the substituents are as defined in the specification, to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them. Formula (I), wherein A represents O or N(R1); Y represents a group of formula, or wherein the left bond is attached to the A group and the right bond is attached to the R group; R represents a substituted or unsubstituted C5-C10aryl, substituted or unsubstituted hetero-C5-C10aryl, a group N(R1)(R4), or a group N(R2)(CHP3R4); R represent a hydrogen, C1-C4alkyl, or CF3; R2 represents hydrogen, C1-C4alkyl, or CF3; R3 represents hydrogen, C1-C4alkyl, or CF3; R4 represents a substituted or unsubstituted C5-C10 aryl or a substituted or unsubstituted C5-C10heteroaryl; in free base or acid addition salt form.